|
rs113488022
|
|
Colorectal Carcinoma
|
T |
0.900 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyrosine kinase signaling.
|
28951457 |
2017 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8-10% of these tumours presenting a BRAF (V600E) mutation.
|
30087414 |
2018 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Colorectal cancer (CRC) with the V600E mutation of B-Raf proto-oncogene serine/threonine kinase (BRAF<sup>V600E</sup>) mutation is insensitive to chemotherapy and is indicative of a poor patient prognosis.
|
30854056 |
2019 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
V599E was observed in 12 of 19 (63%) polyps and 14 of 20 (70%) cancers (4 of 4 high MSI, 2 of 4 low MSI, and 8 of 12 stable MSI), a significant increase over HNPCC (0 of 15 or 0%), and unselected CRC (30 of 197 or 15.2%) ( P < .05).
|
15765445 |
2005 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
A correlation between MLH1 promoter methylation, specifically the 'C' region, and BRAF V600E status has been reported in CRC studies.
|
23880961 |
2014 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.
|
23657789 |
2013 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Activating V600E mutation in BRAF gene has been linked with widespread methylation of CpG islands in sporadic colorectal cancers.
|
21455633 |
2011 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
|
25714871 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Alterations in <i>MEK1/2</i> occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in <i>BRAF</i>-V600E-mutant melanoma and colorectal cancer.
|
28655712 |
2017 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although biased by the fact that germline testing was not pursued beyond direct sequencing in many cases lacking a high clinical index of suspicion of HNPCC, BRAF V600E detection was therefore considered to be 100% specific and 48% sensitive in detecting sporadic MSI-H CRC amongst those cases showing loss of MLH1 protein expression, in a population of patients with MSI-H CRC and clinical features suggestive of HNPCC.
|
17453358 |
2007 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although BRAF(V600E) mutation is associated with adverse clinical outcomes in patients with colorectal cancer (CRC), response and resistance mechanisms for therapeutic BRAF(V600E) inhibitors remains poorly understood.
|
26750638 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
An MAFG-containing corepressor complex induces CIMP in BRAF(V600E)-positive colorectal cancer.
|
25367952 |
2014 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Analysis of DNA mismatch repair proteins expression and BRAF V600E mutation in a subset of early- and late-onset colorectal carcinoma patients in Mexico.
|
21945875 |
2011 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome.
|
26160848 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
|
17060676 |
2006 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
|
26438153 |
2015 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients.
|
21681432 |
2012 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
B-RAF mutations, predominantly the specific V600E mutation and additional alterations in exons 11 and 15, were frequently detected in malignant melanomas, papillary thyroid tumors, and colorectal cancers with microsatellite instability (MSI).
|
16413100 |
2006 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Because vemurafenib has shown limited single-agent clinical activity in BRAF(V600E)-mutant metastatic CRC, we therefore explored a range of combination therapies, with both standard agents and targeted inhibitors in preclinical xenograft models.
|
22180495 |
2012 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was analyzed in CRC patients with MMR deficiencies (microsatellite instability and/or lack of MLH1/MSH2 protein expression) in the EPICOLON population-based study.
|
18096441 |
2008 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorectal cancer, its determination provides a diagnostic exclusion criterion for hereditary nonpolyposis colorectal cancer.
|
19213871 |
2009 |
|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was found in 15.6% of colorectal cancers but at higher frequencies in cancers with proximal location, poor differentiation and microsatellite instability (MSI) (all p < 0.001).
|
20233436 |
2010 |